Pharmaceuticals

Abbott and Fonterra to Form Strategic Alliance for Dairy Farming in China

ABBOTT PARK, Ill. and AUCKLAND, New Zealand, July 11, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) and Fonterra Co-operative Group Ltd today announced the signing of an agreement to develop a proposed dairy farm hub inChina. The strategic alliance, which is subject to Chinese regulatory approval, will...

2014-07-11 02:17 1601

Abbott Builds Long-Term Commitment in China

ABBOTT PARK, Ill., July 11, 2014 /PRNewswire/ -- Today's announcement of a proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott (NYSE: ABT) has made inChina, deepening its commitment in the country. In June, Abbott opened a state-of-the-...

2014-07-11 02:01 1431

Coherus BioSciences Appoints Dr. V. Bryan Lawlis, Jr. to Board of Directors

REDWOOD CITY, Calif., July 9, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), announced today the appointment ofV. Bryan Lawlis, Jr., Ph.D., former President and CEO of Itero Biopharmaceuticals, to its Board of Directors. "It is a privilege to join this talented Board of Directors, an...

2014-07-09 20:00 2197

Taipei Medical University-Taipei Cancer Center Offers a New and Noninvasive Treatment for Bone Cancer Pain

TAIPEI, July 4, 2014 /PRNewswire/ -- Taipei Medical University-Taipei Cancer Center (TMU-TCC) announced today that its Taipei Cancer Center (TCC) is now offering a new technology, ExAblate, to improve the quality of life of patients suffering from painful bone metastases. Taipei Cancer Center, af...

2014-07-04 10:00 1891

AMRI Completes Acquisition of Oso Biopharmaceuticals Manufacturing

ALBANY, N.Y., July 2, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI's strategy to be the preeminent suppli...

2014-07-02 04:22 1562

Synageva BioPharma™ Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency

LEXINGTON, Massachusetts, July 1, 2014 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced today that the global, randomized, double-blind, placebo-controlled Phase ...

2014-07-01 04:02 1491

Economist Intelligence Unit Report Calls for Urgent Global Action to Combat the Growing Tuberculosis Pandemic

LONDON, June 30, 2014 /PRNewswire/ -- A new report on tuberculosis (TB) published today by The Economist Intelligence Unit (EIU) investigates the increasing health challenges posed by TB and calls for new ways to improve the effectiveness of the global response to this pandemic[1]. The report sup...

2014-06-30 20:53 1481

Frost & Sullivan: Indonesia continues to be one of the more attractive markets in ASEAN for foreign healthcare companies

JAKARTA, Indonesia, June 28, 2014 /PRNewswire/ -- Frost & Sullivan is optimistic on growth inIndonesia's Healthcare market, driven by various factors such as investments intoIndonesia and growing availability of healthcare services and access in the country. As the ASEAN region grows,Indonesia wi...

2014-06-28 18:00 1420

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 d...

2014-06-27 21:44 1476

CPhI Istanbul Cements Rapid Pharma Sector Growth in Eurasia, Central Asia and MENA Regions

ISTANBUL, June 26, 2014 /PRNewswire/ -- Successful first edition facilitates international partnerships and continued domestic manufacturing growth Leading events organiser, UBM Live, announces the successful launch of CPhI Istanbul 2014 , which took place on Jun...

2014-06-26 22:00 1318

NPCB Malaysia Issues GMP Certificate to Bilcare Global Clinical Supplies

KUALA LUMPUR, Malaysia, June 26, 2014 /PRNewswire/ -- Bilcare GCS received Certificate of GMP Compliance of Manufacturer from National Pharmaceutical Control Bureau, Ministry of Health, Malaysia. This certificate comes after going through strict inspection conducted in accordance to the stringent gu...

2014-06-26 15:10 1292

Frost & Sullivan: Companion Diagnostics Benefit from Fewer Regulatory Barriers in Europe

LONDON, June 24, 2014 /PRNewswire/ -- With the growth in personalised medicine, there is an increased interest in developing companion diagnostics (CDx) tests or tests that match the right therapy to the patient. In fact, over the past few years, market participants have been entering pharmaceutical...

2014-06-24 20:14 1084

Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis

REDWOOD CITY, Calif., June 24, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA).  The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, g...

2014-06-24 06:57 2101

JHL Biotech Closes $35 Million Series B Financing

HSINCHU, June 20, 2014 /PRNewswire/ -- JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series B financing round of $35 million, led by new investors Milestone Capital and a consortium of Taiwan venture capitalists and individuals, including President In...

2014-06-20 02:30 2065

Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin(R) in Alzheimer's Disease Patients

TEL-AVIV, Israel, June 19, 2014 /PRNewswire/ -- Neurim Pharmaceuticals announced today publication of the results from an exploratory Phase 2 randomized placebo-controlled clinical trial evaluating the safety and efficacy of add-on Circadin® (Prolonged Release melatonin 2mg) to standard therapy in A...

2014-06-19 16:18 1870

AmVac Initiates Phase III Trial with its Lead Vaccine Gynevac for the Treatment of Bacterial Vaginosis

ZUG, Switzerland, June 18, 2014 /PRNewswire/ -- Swiss-based AmVac AG, a private biotech company focused on the development of innovative vaccines, announced today the initiation of a Phase III study with AmVac's lead vaccine Gynevac in Bacterial Vaginosis (BV). The trial aims to confirm the safety a...

2014-06-18 04:24 2209

TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1 Diabetes

PARIS, June 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the first results of the TEENs Registry Study, the largest contemporary real-world study of the care of nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings not only highlighted that over ...

2014-06-17 01:32 1442

Sanofi's Lyxumia(R) (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine

PARIS, June 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar)...

2014-06-17 00:33 1623

Fi Asia-China to Welcome the Global Food Industry to Shanghai this Month

AMSTERDAM, June 16, 2014 /PRNewswire/ -- China's leading nutritional ingredients event, Food ingredients (Fi) Asia China, Health ingredients (Hi) and Natural ingredients (Ni), will take place this month, June 26-28, 2014 in Shanghai, China. This is the premier event in China offering food & beverage...

2014-06-16 21:26 1356

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus(R)

SAN FRANCISCO, June 16, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company and Boehringer Ingelheim presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (...

2014-06-16 14:34 1176
1 ... 3637383940